|
1
|
Bernard HU, Burk RD, Chen Z, van Doorslaer
K, zur Hausen H and de Villiers EM: Classification of
papillomaviruses (PVs) based on 189 PV types and proposal of
taxonomic amendments. Virology. 401:70–79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stanley MA, Pett MR and Coleman N: HPV:
from infection to cancer. Biochem Soc Trans. 35:1456–1460. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aggarwal BB, Shishodia S, Sandur SK,
Pandey MK and Sethi G: Inflammation and cancer: how hot is the
link? Biochem Pharmacol. 72:1605–1621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Balkwill F and Coussens LM: Cancer: an
inflammatory link. Nature. 431:405–406. 2004. View Article : Google Scholar
|
|
5
|
Thomas JO and Travers AA: HMG1 and 2, and
related ‘architectural’ DNA-binding proteins. Trends Biochem Sci.
26:167–174. 2001.
|
|
6
|
Tadie J, Bae HB, Deshane J, et al:
Toll-like receptor 4 engagement inhibits adenosine
5′-monophosphate-activated protein kinase activation through a high
mobility group box 1 protein-dependent mechanism. Mol Med.
18:659–668. 2012.PubMed/NCBI
|
|
7
|
Dai S, Sodhi C, Cetin S, et al:
Extracellular high mobility group box-1 (HMGB1) inhibits enterocyte
migration via activation of Toll-like receptor-4 and increased
cell-matrix adhesiveness. J Biol Chem. 285:4995–5002. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Naugler WE and Karin M: NF-kappaB and
cancer-identifying targets and mechanisms. Curr Opin Genet Dev.
18:19–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fiuza C, Bustin M, Talwar S, et al:
Inflammation-promoting activity of HMGB1 on human microvascular
endothelial cells. Blood. 101:2652–2660. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Poser I, Golob M, Buettner R and
Bosserhoff AK: Upregulation of HMG1 leads to melanoma inhibitory
activity expression in malignant melanoma cells and contributes to
their malignancy phenotype. Mol Cell Biol. 23:2991–2998. 2003.
View Article : Google Scholar
|
|
11
|
Weng H, Deng Y, Xie Y, Liu H and Gong F:
Expression and significance of HMGB1, TLR4 and NF-κB p65 in human
epidermal tumors. BMC Cancer. 13:3112013.
|
|
12
|
Frazer IH: Interaction of human
papillomaviruses with the host immune system: a well evolved
relationship. Virology. 384:410–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scott M, Nakagawa M and Moscicki AB:
Cell-mediated immune response to human papillomavirus infection.
Clin Diagn Lab Immunol. 8:209–220. 2001.PubMed/NCBI
|
|
14
|
Gröne A: Keratinocytes and cytokines. Vet
Immunol Immunopathol. 88:1–12. 2002.
|
|
15
|
Locksley RM, Killeen N and Lenardo MJ: The
TNF and TNF receptor superfamilies: integrating mammalian biology.
Cell. 104:487–501. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vaccari T, Beltrame M, Ferrari S and
Bianchi ME: Hmg4, a new member of the Hmg1/2 gene family. Genomics.
49:247–252. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeh HJ III and Lotze MT: Addicted to
death: invasive cancer and the immune response to unscheduled cell
death. J Immunother. 28:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ulloa L and Messmer D: High-mobility group
box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev.
17:189–201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim SW, Lim CM, Kim JB, et al:
Extracellular HMGB1 released by NMDA treatment confers neuronal
apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotox Res.
20:159–169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nogueira-Machado JA, Volpe CM, Veloso CA
and Chaves MM: HMGB1, TLR and RAGE: a functional tripod that leads
to diabetic inflammation. Expert Opin Ther Targets. 15:1023–1035.
2011. View Article : Google Scholar
|
|
21
|
Kawai T and Akira S: The roles of TLRs,
RLRs and NLRs in pathogen recognition. Int Immunol. 21:317–337.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hasan UA, Bates E, Takeshita F, et al:
TLR9 expression and function is abolished by the cervical
cancer-associated human papillomavirus type 16. J Immunol.
178:3186–3197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Verma IM, Stevenson JK, Schwarz EM, Van
Antwerp D and Miyamoto S: Rel/NF-kappa B/I kappa B family: intimate
tales of association and dissociation. Genes Dev. 9:2723–2735.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ghosh S, May MJ and Kopp EB: NF-kappa B
and Rel proteins: evolutionarily conserved mediators of immune
responses. Annu Rev Immunol. 16:225–260. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ghosh S and Hayden MS: New regulators of
NF-kappaB in inflammation. Nat Rev Immunol. 8:837–848. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karin M and Greten FR: NF-kappaB: linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005. View
Article : Google Scholar : PubMed/NCBI
|
